These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7574508)

  • 41. [Pharmacokinetics of cefixime in healthy volunteers after a single oral administration of 200 mg].
    Montay G; Le Liboux A; Thebault JJ; Roche G; Frydman A; Gaillot J
    Presse Med; 1989 Oct; 18(32):1583-6. PubMed ID: 2530537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
    Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacokinetics of cefixime in patients with impaired renal function].
    Maeda H; Sako M; Fujii A; Yamazaki H; Kawabata G; Harada M; Arakawa S; Umezu K; Kamidono S; Ishigami J
    Jpn J Antibiot; 1986 Oct; 39(10):2716-20. PubMed ID: 3806957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fundamental and clinical studies on cefixime in pediatrics].
    Iwai N; Shibata M; Mizoguchi F; Nakamura H; Katayama M
    Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Research and development of new oral cephems, cefixime and cefdinir].
    Sakane K; Kawabata K; Inamoto Y; Yamanaka H; Takaya T
    Yakugaku Zasshi; 1993 Sep; 113(9):605-26. PubMed ID: 8229662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the use of cefixime for switch therapy.
    Low DE
    Infection; 1995; 23 Suppl 2():S91-4. PubMed ID: 8537140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetic interaction of cefixime and 2 antacids. Preliminary results].
    Petitjean O; Brion N; Tod M; Montagne A; Nicolas P
    Presse Med; 1989 Oct; 18(32):1596-8. PubMed ID: 2530541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media.
    Magit AE; Dolitsky JN; Doyle WJ; Swarts JD; Seroky JT; Rosenfeld RM
    Int J Pediatr Otorhinolaryngol; 1994 Mar; 29(1):1-9. PubMed ID: 8169042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].
    Kees F; Naber KG
    Infection; 1990; 18 Suppl 3():S150-4. PubMed ID: 2079377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefixime.
    Leggett NJ; Caravaggio C; Rybak MJ
    DICP; 1990 May; 24(5):489-95. PubMed ID: 2188437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
    Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
    J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
    Cappelletty DM; Rybak MJ
    Antimicrob Agents Chemother; 1996 May; 40(5):1148-52. PubMed ID: 8723456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Determination of cefixime in human plasma and urine using high performance liquid chromatography column switching technique].
    Liu GL; Sha RG; Gao S; Shen YX; Wang SX
    Yao Xue Xue Bao; 1993; 28(3):216-21. PubMed ID: 8368083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HPLC assay of cefixime in serum and CSF.
    White LO; Reeves DS; Lovering AM; MacGowan AP
    J Antimicrob Chemother; 1993 Mar; 31(3):450-1. PubMed ID: 8486584
    [No Abstract]   [Full Text] [Related]  

  • 56. The pharmacokinetics of cefixime in the fasted and fed state.
    Faulkner RD; Bohaychuk W; Haynes JD; Desjardins RE; Yacobi A; Silber BM
    Eur J Clin Pharmacol; 1988; 34(5):525-8. PubMed ID: 3203716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of cefixime on the normal intestinal microflora.
    Nord CE; Movin G; Stålberg D
    Scand J Infect Dis; 1988; 20(5):547-52. PubMed ID: 3222669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical study on cefixime granules in the field of pediatrics].
    Haruta T; Kuroki S; Kobayashi Y
    Jpn J Antibiot; 1986 Apr; 39(4):1106-14. PubMed ID: 3761540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cefotaxime concentrations in the blood and kidney].
    Fujita K; Fujita HM; Hata M; Ohmi Y; Ohta N; Ohtawara Y; Aso Y
    Jpn J Antibiot; 1983 Jun; 36(6):1461-4. PubMed ID: 6317905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.